By providing an additional benefit of weight loss, GLP1 RAs represent the preferable second-line option for patients with obesity and inadequately controlled T2D, as adjunct to lifestyle interventions and metformin [55]. This evidence concerns the gene GCG and type 2 diabetes mellitus.